<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02675855</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol 350</org_study_id>
    <nct_id>NCT02675855</nct_id>
  </id_info>
  <brief_title>GrafixPRIME® for the Treatment of Chronic Diabetic Foot Ulcers</brief_title>
  <official_title>A Multicenter, Randomized, Single-Blind Study Comparing the Efficacy of GrafixPRIME® to Active Comparator for the Treatment of Chronic Diabetic Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osiris Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Osiris Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to compare the efficacy of weekly GrafixPRIME® administration
      to an Active Comparator in patients with chronic DFUs in a randomized, single-blind study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete closure of index wound</measure>
    <time_frame>Up to Day 56</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to wound closure</measure>
    <time_frame>Up to Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients that achieve a 50% reduction or greater in wound size</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of product applications</measure>
    <time_frame>Up to Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>Up to Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with worsening of wound by ≥50% increase in size</measure>
    <time_frame>Up to Day 56</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Foot Ulcer, Diabetic</condition>
  <arm_group>
    <arm_group_label>GrafixPRIME®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GrafixPRIME® is cryopreserved human placental membrane Patients will be fitted with off-loading devices</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Wound cover, Dressing Application Patients will be fitted with off-loading devices</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GrafixPRIME®</intervention_name>
    <description>Human tissue, Wound cover, Application of a non-adherent dressing, a moisture retentive dressing, and a secondary dressing.</description>
    <arm_group_label>GrafixPRIME®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dressing Application</intervention_name>
    <description>Wound cover, Application of a non-adherent dressing, a moisture retentive dressing, and a secondary dressing.</description>
    <arm_group_label>Active Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Off-loading (walking boot)</intervention_name>
    <description>Patients will be fitted for an off-loading device (walking boot) and agree to comply with use of the device during the course of the study</description>
    <arm_group_label>GrafixPRIME®</arm_group_label>
    <arm_group_label>Active Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 or Type 2 Diabetes

          -  Chronic ulcer (present for ≥4 weeks, but not more than 52 weeks)

          -  Index ulcer located below the malleoli on the plantar or dorsal surface of the foot

          -  Index ulcer extends into the dermis or subcutaneous tissue without evidence of exposed
             muscle, tendon, bone or joint capsule

          -  Adequate circulation to the foot (documented by ABI or TBI)

        Exclusion Criteria:

          -  Gangrene present on affected foot

          -  Index ulcer is over a Charcot deformity

          -  Patient is receiving dialysis

          -  Patient has 2 or more previous amputations

          -  Patient has HbA1c &gt;12% or random blood sugar &gt;450 mg/dl

          -  Chronic oral steroid use

          -  Use of IV corticosteroid, immunosuppressive, or cytotoxic agents

          -  IV antibiotics

          -  Another ulcer within 5cm of the Index ulcer

          -  Cellulitis, evidence of infection, or osteomyelitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharron McCulloch</last_name>
    <role>Study Director</role>
    <affiliation>Director, Clinical Affairs</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Arizona</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>California City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Mexico</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2016</study_first_submitted>
  <study_first_submitted_qc>February 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2016</study_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Grafix</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

